Reduction of morbidity by immunoadsorption therapy in patients with dilated cardiomyopathy

Knebel, Fabian; Böhm, M; Staudt, Alexander; Borges, Adrian C.; Tepper, Mirko; Jochmann, Nicoline; Wernicke, K.; Felix, Stephan B.; Baumann, Gert

doi:10.1016/j.ijcard.2003.12.003

Cited by 47 publications

(38 citation statements)

References 13 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a following retrospective study, patients with congestive heart failure (CHF) or DCM (NYHA class II-III; LVES Ͻϭ35%) who received IA therapy showed significantly decreased hospitalization rate compared to CHF-or DCM-controls during 3 years follow up. 106 In further studies, it has been shown that apart from improving cardiac hemodynamic parameters in DCM patients, IA influences the cellular component of the adaptive immune system. 111 From 25 DCM patients (ejection fraction [EF] Ͻ30%), 12 patients were randomized for IA therapy and subsequent IgG substitution at 1-month intervals until month 3.…”

Section: Autoantibodies As a Clinical Target For Therapy Of Heart Faimentioning

confidence: 98%

Autoantibodies in Heart Failure and Cardiac Dysfunction

Kaya

Leib

Katus

2012

Circulation Research

162

151

View full text Add to dashboard Cite

Abstract:Human heart failure is a disease with multifactorial causes, considerable morbidity, and high mortality.Several circulating autoantibodies, some of them being heart-specific, play a crucial role in the progression and induction of heart failure. However the precise mechanisms on how these autoantibodies perpetuate or even induce an organ specific autoimmune response are not yet fully understood. Also it is being a matter of current research to elucidate a potential pathophysiological role of the innate immune system in generating auto-reactive antibodies. In this review we will summarize the current available literature on circulating autoantibodies which are related to human heart failure. We will present clinical and animal studies that demonstrate the occurrence and pathophysiological relevance of several autoantibodies in heart failure, as well as point out biological mechanisms on molecular and cellular level. Finally the beneficial therapeutic effects of numerous clinical studies that target the humoral arm of the immune system by using either intravenous immunoglobulins and/or immunoadsorption will be critically discussed. (Circ Res. 2012;110:145-158.)

show abstract

Section: Autoantibodies As a Clinical Target For Therapy Of Heart Faimentioning

confidence: 98%

Autoantibodies in Heart Failure and Cardiac Dysfunction

Kaya

Leib

Katus

2012

Circulation Research

162

151

View full text Add to dashboard Cite

show abstract

“…There have been over 80 patients treated in controlled studies and the data suggests that removal of anticardiac IgG may confer clinical benefit [28,[38][39][40]. For our studies, we elected to use therapeutic plasma exchange; a widely clinical accessible and established therapeutic strategy for a number of clinical conditions [41][42][43][44].…”

Section: Therapeutic Plasma Exchange As a Therapeutic Strategy For Pamentioning

confidence: 99%

Therapeutic plasma exchange a potential strategy for patients with advanced heart failure

Torre‐Amione

Orrego

Khalil

et al. 2010

J of Clinical Apheresis

View full text Add to dashboard Cite

show abstract

“…Observation over longer period may be required to confirm the effects on LVEF. In addition, some previous studies used immunoglobulin substitution after IA [9,10,[12][13][14]. Therefore, it is difficult to simply compare the efficacy of these columns from this study.…”

Section: Identification Of Respondersmentioning

confidence: 98%

“…Second, the substitution of immunoglobulin agents is not required. In some previous reports used protein A columns and anti-Ig columns immunoglobulin substitution was required for the risk of infection after IA [9,10,[12][13][14], although it was not necessary in others [11,22,23]. The use of immunoglobulin substitution may have therapeutic efficacy, since IV immunoglobulin treatment also influences the immune system by means of var- Fig.…”

Section: Tryptophan Columnmentioning

confidence: 99%